# Discovery and anti-tumor activity of the first antagonists targeting human Sonic Hedgehog autoprocessing

> **NIH NIH R21** · STATE UNIVERSITY OF NY,BINGHAMTON · 2024 · $182,116

## Abstract

ABSTRACT
We are pursuing the first anti-tumor small molecules that act specifically against human Sonic Hh protein
autoprocessing, a unique biosynthetic event that is necessary to drive oncogenic hedgehog (Hh) ligand
dependent cell/cell signaling. Sonic Hh protein autoprocessing involves a precursor form of Hh and is
responsible for liberating the mature Sonic Hh signaling ligand while also modifying the ligand’s terminal
carboxyl group with cholesterol. The long-standing challenge has been to discover small molecules that
specifically antagonize this key reaction within the tumor cell. To facilitate discovery, we have devised the
first in-cell assay system to screen for antagonists of human Hh autoprocessing at high throughput. Our
assay couples intracellular Sonic Hh autoprocessing to the extracellular secretion of a bioluminescent
reporter enzyme. We recently miniaturized this assay for 1536-well plates and in preliminary work,
completed a successful pilot screen against LOPAC. Here we propose a two-year high risk/gain strategy
that integrates: (AIM 1) In-cell quantitative high throughput screening in collaboration with the National
Center for Advancing Translational Science (NCATS) to discover the first bioactive drug-like antagonists
of human Sonic Hh autoprocessing; (AIM 2) Pre-clinical evaluation of the anti-tumor effects of those novel
Hh autoprocessing inhibitors toward human multiple myeloma and human colon cancer cells, which exhibit
Hh-ligand dependent growth. We hypothesize that specific antagonists of Sonic Hh autoprocessing will
deplete extracellular Sonic Hh ligand. Tumor apoptosis is the expected result of this ligand deprivation
strategy. In summary, using an innovative assay and novel anti-Hh approach, we are poised to address a
significant gap in the field of Hh signaling while pursuing a new class of cancer therapeutics.

## Key facts

- **NIH application ID:** 10865276
- **Project number:** 1R21CA282857-01A1
- **Recipient organization:** STATE UNIVERSITY OF NY,BINGHAMTON
- **Principal Investigator:** Brian Patrick Callahan
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $182,116
- **Award type:** 1
- **Project period:** 2024-03-06 → 2026-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10865276

## Citation

> US National Institutes of Health, RePORTER application 10865276, Discovery and anti-tumor activity of the first antagonists targeting human Sonic Hedgehog autoprocessing (1R21CA282857-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10865276. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*